About maribavir
Antiviral; cytomegalovirus pUL UL97 kinase inhibitor
Used for
- Treats cytomegalovirus infection after transplant when other antiviral medicines have not worked or cannot be used.
Usual adult dose
400 mg by mouth twice daily for eight weeks; treatment may be extended based on response.
Common side effects
- Taste changes
- Nausea
- Diarrhea
- Vomiting
Important warnings
- Not for prevention of cytomegalovirus infection.
- May cause antiviral resistance if treatment fails.
- Do not take with ganciclovir or valganciclovir.
- Monitor transplant recipients for infection and graft complications.
Pregnancy
Human pregnancy data are insufficient to determine risks.
Breastfeeding
It is unknown whether maribavir enters human milk; breastfeeding risks are not established.
Interactions
- Can reduce levels of tacrolimus, cyclosporine, sirolimus, and everolimus; monitor drug levels.
- Strong enzyme-inducing medicines, including rifampin, can lower maribavir levels.
- Maribavir can increase levels of certain medicines, including digoxin and some statins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.